Patent application number | Description | Published |
20080206201 | Recombinant Newcastle Disease Virus - The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof. | 08-28-2008 |
20090081207 | High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity - The present invention relates to recombinant human or humanized polypeptides which bind to α5β1 integrin with high affinity and blocking function. Further, diagnostic and pharmaceutic applications of the potypeptides are disclosed. | 03-26-2009 |
20100183505 | IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES - The present invention relates to the use of radioimmunoconjugates for the treatment of haematological malignancies, particularly multiple myeloma. | 07-22-2010 |
20110020282 | RECOMBINANT NEWCASTLE DISEASE VIRUS - The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof. | 01-27-2011 |